BRCA2 and neoplasm: We previously reported that none of the PARPi-resistant BRCA2-deficient tumours restored RAD51 IRIF12, whereas 64% (29/45) of the BRCA1-deficient tumours became RAD51 IRIF+ (Fig. 1e).